Alexandra Toohey
@Baker Bros. Advisors Lp
Latest period2024 - Q3ReportedManaged Assets$9.649BTotal holdings93
Assets growth rate23.31%Assets growth rate (2-Q avg)10.74%Continuous growth in asset value1 quarters
Portfolio positions
This chart displays the top 10 holdings in Baker Bros. Advisors Lp's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 93 positions.
Assets under management
The assets under management (AUM) of Baker Bros. Advisors Lp over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 9.649B in assets, with a quarterly growth rate of 23.31% and a 2-quarter average growth rate of 10.74%. The portfolio is managed by Alexandra Toohey, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
FATEFate Therapeutics, Inc.
| 0.11% | $10.492M 2.998M shares@ $3.5 avg price | |
ARVNArvinas, Inc.
| 0.11% | $9.989M 405,576 shares@ $24.64 avg price | New Position |
SANASana Biotechnology, Inc.
| 0.11% | $9.905M 2.381M shares@ $4.17 avg price | |
DSGNDesign Therapeutics, Inc.
| 0.1% | $9.381M 1.744M shares@ $5.39 avg price | Increased 2.86% |
IONSIonis Pharmaceuticals, Inc.
| 0.1% | $8.952M 223,470 shares@ $40.06 avg price | New Position |
OPTOpthea Limited
| 0.1% | $8.847M 2.174M shares@ $4.08 avg price | |
CLDXCelldex Therapeutics, Inc.
| 0.09% | $8.417M 247,644 shares@ $34.0 avg price | |
RLAYRelay Therapeutics, Inc.
| 0.09% | $8.214M 1.16M shares@ $7.08 avg price | |
VERVVerve Therapeutics, Inc.
| 0.09% | $8.187M 1.692M shares@ $4.84 avg price | |
TSHATaysha Gene Therapies, Inc.
| 0.09% | $8.05M 4.005M shares@ $2.02 avg price |